Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

Halozyme Therapeutics (NASDAQ:HALO) announced Monday that the European Commission has approved an injectable version of Johnson & Johnson’s (NYSE:JNJ) antitumor agent Rybrevant for certain patients ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and ...

The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...